Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have received a consensus rating of “Moderate Buy” from the thirteen brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, nine have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $99.55.
HALO has been the subject of several research analyst reports. HC Wainwright boosted their price objective on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Stifel Nicolaus set a $130.00 target price on Halozyme Therapeutics in a report on Friday, October 16th. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, August 31st. Finally, JPMorgan Chase & Co. boosted their price target on Halozyme Therapeutics from $70.00 to $78.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th.
Read Our Latest Report on HALO
Halozyme Therapeutics Trading Up 0.4%
Shares of Halozyme Therapeutics stock opened at $128.50 on Friday. Halozyme Therapeutics has a 12-month low of $61.22 and a 12-month high of $128.94. The firm’s 50-day moving average price is $112.23 and its two-hundred day moving average price is $82.58.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts anticipate that Halozyme Therapeutics will post 8.31 EPS for the current year.
Insider Buying and Selling at Halozyme Therapeutics
In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 18,996 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the completion of the transaction, the director directly owned 58,839 shares of the company’s stock, valued at $6,339,313.86. This trade represents a 24.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 125,852 shares of company stock worth $13,538,046 over the last 90 days. Insiders own 2.50% of the company’s stock.
Institutional Investors Weigh In On Halozyme Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in HALO. BOKF NA boosted its holdings in shares of Halozyme Therapeutics by 1.8% during the 3rd quarter. BOKF NA now owns 15,811 shares of the biopharmaceutical company’s stock valued at $1,746,000 after acquiring an additional 286 shares in the last quarter. Hanseatic Management Services Inc. bought a new position in Halozyme Therapeutics in the third quarter valued at about $303,000. North Dakota State Investment Board raised its position in Halozyme Therapeutics by 4.3% in the third quarter. North Dakota State Investment Board now owns 3,598 shares of the biopharmaceutical company’s stock valued at $397,000 after purchasing an additional 147 shares during the last quarter. Roman Butler Fullerton & Co. bought a new position in Halozyme Therapeutics in the third quarter valued at about $489,000. Finally, Oppenheimer & Co. Inc. boosted its stake in shares of Halozyme Therapeutics by 39.6% during the third quarter. Oppenheimer & Co. Inc. now owns 22,013 shares of the biopharmaceutical company’s stock valued at $2,430,000 after purchasing an additional 6,241 shares in the last quarter. 97.79% of the stock is owned by institutional investors.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.
Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.
Featured Stories
- Five stocks we like better than Halozyme Therapeutics
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}